TY - JOUR
T1 - ARIA guideline 2019: treatment of allergic rhinitis in the German health system
AU - Klimek, Ludger
AU - Bachert, Claus
AU - Pfaar, Oliver
AU - Becker, Sven
AU - Bieber, Thomas
AU - Brehler, Randolf
AU - Buhl, Roland
AU - Casper, Ingrid
AU - Chaker, Adam
AU - Czech, Wolfgang
AU - Fischer, Jörg
AU - Fuchs, Thomas
AU - Gerstlauer, Michael
AU - Hörmann, Karl
AU - Jakob, Thilo
AU - Jung, Kirsten
AU - Kopp, Matthias V.
AU - Mahler, Vera
AU - Merk, Hans
AU - Mülleneisen, Norbert
AU - Nemat, Katja
AU - Rabe, Uta
AU - Ring, Johannes
AU - Saloga, Joachim
AU - Schlenter, Wolfgang
AU - Schmidt-Weber, Carsten
AU - Seyfarth, Holger
AU - Sperl, Annette
AU - Spindler, Thomas
AU - Staubach, Petra
AU - Strieth, Sebastian
AU - Treudler, Regina
AU - Vogelberg, Christian
AU - Wallrafen, Andrea
AU - Wehrmann, Wolfgang
AU - Wrede, Holger
AU - Zuberbier, Torsten
AU - Bedbrook, Anna
AU - Canonica, Giorgio W.
AU - Cardona, Victoria
AU - Casale, Thomas B.
AU - Czarlewski, Wienczylawa
AU - Fokkens, Wytske J.
AU - Hamelmann, Eckard
AU - Hellings, Peter W.
AU - Jutel, Marek
AU - Larenas-Linnemann, Désirée
AU - Mullol, Joaquim
AU - Papadopoulos, Nikolaos G.
AU - Toppila-Salmi, Sanna
AU - Werfel, Thomas
AU - Bousquet, Jean
N1 - Funding Information:
C. Bachert reports personal fees from Mylan, Stallergenes and ALK, outside the submitted work. S. Becker reports personal fees from ALK, Allergopharma, HAL Allergy, Bencard Allergy, Sanofi-Genzyme, Thermo Fisher Scientific and B.R.A.I.N AG, grants and personal fees from PARI GmbH, outside the submitted work. T. Bieber reports personal fees from Sanofi, Novartis, AbbVIe, Galderma, Pfizer, Lilly, Kymab, outside the submitted work. J. Bousquet reports personal fees from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Purina, Sanofi-Aventis, Takeda, Teva, Uriach, other from KYomed-Innov, outside the submitted work. R. Brehler reports personal fees form Berufsgenossenschaften, Gerichten, ÄK Nordwürttemberg, ÄK Westfalen-Lippe, ALK, Allergopharma, Allmiral, Apothekerkammer, Astra Zeneca, Bencard, DPC, Gesellschaft zur Förderung der Dermatologischen Forschung und Fortbildung, GSK, HAL, HNO-Gesellschaft, Leti, Novartis, Pohl-Boskamp, Pfleger, Phadia, Update GmbH, Stallergenes, grants from Biotechtools, Genentech, Novartis, Bencard, HAL, AstraZeneca, ALK, outside the submitted work. V. Cardona reports personal fees from ALK, Allergopharma, Allergy Therapeutics, Diater, LETI, Thermofisher and Stallergenes, outside the submitted work. J. Mullol reports personal fees from ALK-Abelló, Sanofi-Genzyme & Regeneron, Menarini Group, MSD, Mitsubishi-Tanabe, Novartis, UCB Pharma, GENENTECH - Roche, grants and personal fees from URIACH Group, MYLAN-MEDA Pharma, outside the submitted work. H.F. Merk reports personal fees from MEDA, Grünenthal and Coty, outside the submitted work. T. Jakob reports grants, personal fees and non-financial support from Novartis, ALK Abello, personal fees and non-financial support from Bencard/Allergy Therapeutics, personal fees from Allergopharma, Thermo Fisher Scientific and Celgene, outside the submitted work. M. Jutel reports personal fees from ALK-Abello, Allergopharma, Stallergenes, Anergis, Allergy Therapeutics, Circassia, Leti, Biomay, HAL, during the conduct of the study; personal fees from Astra-Zeneka, GSK, Novartis, Teva, Vectura, UCB, Takeda, Roche, Janssen, Medimmune and Chiesi, outside the submitted work. L. Klimek reports grants and personal fees from ALK Abelló, Novartis, Allergopharma, Bionorica, GSK and Lofarma; personal fees from Boehringer Ingelheim and MEDA, grants from Biomay, HAL, LETI, Roxall, Bencard, outside the submitted work. P. Hellings reports grants and personal fees from Mylan, during the conduct of the study; personal fees from Sanofi, Allergopharma and Stallergenes, outside the submitted work. J. Saloga reports personal fees from ALK-Abelló, Novartis Pharma and Thermo Fisher, outside the submitted work. C. Schmidt-Weber reports grants from DFG, DZL, during the conduct of the study; personal fees and/or grants from Bencard, Allergopharma, Leti Pharma, outside the submitted work. In addition, he has a patent on AIT biomarker. S. Strieth reports grants from Deutsche Forschungsgemeinschaft (DFG), Stiftung Tumorforschung Kopf-Hals, grants Andreas Fahl Medizintechnik-Vertrieb, Atos Medical, Tracoe Medical, Heimomed Heinze, Bromepithetik, Fresenius Kabi and non-financial support from MED-EL AG, personal fees from Auris Medical, Merck Serono, Otonomy, Inc., Nordmark Arzneimittel, Sonofi Genzyme, ALK-Abelló Arzneimittel, outside the submitted work. R. Treudler reports grants and personal fees from Sanofi-Genzyme, personal fees from ALK-Abello, Takeda, Novartis, grants from Hautnetz Leipzig, other from Fraunhofer-IZI Leipzig, outside the submitted work. S. Toppila-Salmi reports consultancy for Mylan Laboratories Ltd, ERT Ltd, Roche Products Ltd, outside the submitted work. C. Vogelberg reports grants and/or personal fees from ALK Abello, Allergopharma, AstraZeneca, Boehringer Ingelheim, Bencard Allergy, DBV Technologies, Novartis Pharma and Sanofi Avensis, outside the submitted work. A. Bedbrook, R. Buhl, G.W. Canonica, T.B. Casale, I. Casper, A. Chaker, W. Czarlewski, W. Czech, J. Fischer, K. Nemat, N.G. Papadopoulos, O. Pfaar, U. Rabe, M. Kopp, D. Larenas-Linnemann, V. Mahler, N. Mülleneisen, K. Hörmann, K. Jung, W. Fokkens, T. Fuchs, M. Gerstlauer, E. Hamelmann, J. Ring, W. Schlenter, H. Seyfarth, A. Sperl, T. Spindler, P. Staubach, A. Wallrafen, W. Wehrmann, T. Werfel, H. Wrede and T. Zuberbier declare that they have no competing interests.
Publisher Copyright:
© 2019, The Author(s).
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2019/11/1
Y1 - 2019/11/1
N2 - Background: The number of patients affected by allergies is increasing worldwide. The resulting allergic diseases are leading to significant costs for health care and social systems. Integrated care pathways are needed to enable comprehensive care within the national health systems. The ARIA (Allergic Rhinitis and its Impact on Asthma) initiative develops internationally applicable guidelines for allergic respiratory diseases. Methods: ARIA serves to improve the care of patients with allergies and chronic respiratory diseases. In collaboration with other international initiatives, national associations and patient organizations in the field of allergies and respiratory diseases, real-life integrated care pathways have been developed for a digitally assisted, integrative, individualized treatment of allergic rhinitis (AR) with comorbid asthma. In the present work, these integrated care pathways have been adapted to the German situation and health system. Results: The present ICP (integrated care pathways) guideline covers key areas of the care of AR patients with and without asthma. It includes the views of patients and other healthcare providers. Discussion: A comprehensive ICP guideline can reflect real-life care better than traditional guideline models.
AB - Background: The number of patients affected by allergies is increasing worldwide. The resulting allergic diseases are leading to significant costs for health care and social systems. Integrated care pathways are needed to enable comprehensive care within the national health systems. The ARIA (Allergic Rhinitis and its Impact on Asthma) initiative develops internationally applicable guidelines for allergic respiratory diseases. Methods: ARIA serves to improve the care of patients with allergies and chronic respiratory diseases. In collaboration with other international initiatives, national associations and patient organizations in the field of allergies and respiratory diseases, real-life integrated care pathways have been developed for a digitally assisted, integrative, individualized treatment of allergic rhinitis (AR) with comorbid asthma. In the present work, these integrated care pathways have been adapted to the German situation and health system. Results: The present ICP (integrated care pathways) guideline covers key areas of the care of AR patients with and without asthma. It includes the views of patients and other healthcare providers. Discussion: A comprehensive ICP guideline can reflect real-life care better than traditional guideline models.
UR - http://www.scopus.com/inward/record.url?scp=85074226044&partnerID=8YFLogxK
U2 - 10.1007/s40629-019-00110-9
DO - 10.1007/s40629-019-00110-9
M3 - Journal articles
AN - SCOPUS:85074226044
SN - 2197-0378
VL - 28
SP - 255
EP - 276
JO - Allergo Journal International
JF - Allergo Journal International
IS - 7
ER -
